ADVA
7.4.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Bank Otkritie has deployed its FSP 3000 to enable 32Gbit/s Fibre Channel as well as 40 and 100Gbit/s Ethernet services. One of Russia's largest commercial financial companies, Bank Otkritie is the first bank in the country to leverage Gen 6 Fibre Channel technology. Featuring the ADVA OpenFabric™ OTN cross-connect for enhanced availability, the data center interconnect (DCI) solution delivers a new level of capacity and reliability. Comprehensive, in-service assurance and rapid failure detection capabilities are provided by the ADVA ALM fiber monitoring system. ADVA’s Select partner, the IT solution specialist Zettaline, also played a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005043/en/
“As one of Russia’s leading banks, it’s vital that we provide our customers with continuous access to their mission-critical financial data. That’s why the ADVA FSP 3000 combined with OpenFabric™ and ALM assurance technology is the ideal tool. It ensures comprehensive monitoring and testing for the highest network availability and service reliability,” said Andrey Ivashenko, VP and CIO, Bank Otkritie. “By supporting 32Gbit/s Fibre Channel, this new solution has taken our storage data transport to the next stage. And, with the ADVA FSP 3000 OpenFabric™ aggregating lower-speed services onto high-speed wavelengths, we have the power to efficiently provide the data rates that our individual customers require.”
Built on the ADVA FSP 3000, a uniquely compact and efficient optical transport solution, Bank Otkritie’s new DCI network saves significantly on opex. The infrastructure delivers high-capacity Ethernet and Fibre Channel connectivity while consuming extremely low levels of power, helping Bank Otkritie to hit ambitious energy targets even as traffic continues to grow. Featuring ADVA’s OpenFabric™ OTN cross-connect, the new solution also offers ultimate flexibility, enabling services to be turned up remotely and easily. What’s more, the scalable modular design of the platform protects Bank Otkritie’s investment and empowers the company to plan for further expansion.
“Bank Otkritie’s new network provides a significant boost in terms of capacity and efficiency. With our FSP 3000 technology, it supports the most advanced low-latency Fibre Channel services, enabling the bank to maximize the performance of flash-enhanced storage in its data centers,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “Robustness and reliability were key to this project. That’s why Bank Otkritie also selected our ALM solution. Specifically engineered to be a simple plug-and-play fiber assurance device, it provides continuous monitoring, enabling operators to know immediately if and where issues arise. This real-time data is key to supervising and assuring dark fiber services. And, in the event of any fiber issues, our FSP 3000 OpenFabric™ automatically discovers new paths, enhancing availability and quality of service.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom